Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in ASND held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 225K | $60.1M | +68.9% | 0.363% | 1.31% |
| 2 | Neuberger Berman Group LLC | 143K | $38.1M | — | 0.230% | 0.01% |
| 3 | ODDO BHF ASSET MANAGEMENT SAS | 129K | $34.3M | 0.0% | 0.207% | 1.59% |
| 4 | Quadrature Capital Ltd | 41K | $10.9M | — | 0.066% | 0.09% |
| 5 | Ninepoint Partners LP | 5K | $1.2M | — | 0.009% | 0.05% |
| 6 | FERGUSON WELLMAN CAPITAL MANAGEMENT, INC | 3K | $693K | 0.0% | 0.004% | 0.01% |
| 7 | DEARBORN PARTNERS LLC | 1K | $347K | 0.0% | 0.002% | 0.01% |
| 8 | E Fund Management (Hong Kong) Co., Ltd. | 84 | $22K | +40.0% | 0.000% | 0.01% |
| 9 | IFP Advisors, Inc | 14 | $3K | +16.7% | 0.000% | 0.00% |
| 10 | HUNTINGTON NATIONAL BANK | 1 | $244 | 0.0% | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in ASND — a direct measure of their conviction.
Filings activity in ASND during Q2 2026, grouped by how each filer changed its position.
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 10 | 96% | 0.88% | 89.57 pp | $146M | 99% |
| Q1 2026 | 274 | 10% | 90.45% | 14.42 pp | $12.77B | 3.3% |
| Q4 2025 | 305 | +7.4% | 104.87% | 5.70 pp | $13.20B | +12% |
| Q3 2025 | 284 | +17% | 110.57% | +8.64 pp | $11.81B | +21% |
| Q2 2025 | 242 | +3.0% | 101.93% | 2.07 pp | $9.72B | +8.7% |
| Q1 2025 | 235 | +12% | 104.00% | +1.97 pp | $8.94B | +17% |
| Q4 2024 | 210 | 2.3% | 102.03% | +0.95 pp | $7.64B | 8.6% |
| Q3 2024 | 215 | — | 101.08% | — | $8.36B | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Latest Form 4 transactions by company officers and directors. Insider buys are widely viewed as a key fundamental indicator because executives are risking personal capital.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| May 29, 2026 | SMITH SCOTT THOMAS | Buy | 250 | $223.32 | $56K |
| May 29, 2026 | BIENAIME JEAN JACQUES | Buy | 200 | $223.76 | $45K |
| May 26, 2026 | BIENAIME JEAN JACQUES | Buy | 200 | $236.24 | $47K |
Institutional ownership and quarterly buying activity across the largest Rare Disease Biotech peers.
| Ticker | Company | Market Cap | Inst. Ownership | Holders | Net Buyers − Sellers |
|---|---|---|---|---|---|
| IRLA | IRulya Therapeutics Inc. | $39M | 23.9% | 42 | -29 |
Quick answers to the most common questions about buying ASND stock.
Based on Q2 2026 13F filings, institutional ownership of Ascendis Pharma A/S stands at 0.9%, held across 10 reporting institutions.
Frazier Life Sciences Management, L.P. is the largest reported institutional holder of ASND, with approximately 225,155 shares worth $0.06B as of Q2 2026.
No marquee "smart money" managers (Berkshire, Burry, ARK, Tiger Global, Pershing Square, Baupost, etc.) currently appear among the top 25 institutional holders of ASND.
Our composite Smart Money Score for ASND is 0 out of 100 (Heavy Distribution). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
2 institutions opened new positions in ASND during Q2 2026, while 264 fully exited. 7 added to existing positions and 0 trimmed.
ASND institutional ownership fell by 89.57 percentage points quarter-over-quarter, with a net change of -264 holders.
The top 10 institutions account for 100.0% of all reported 13F value in ASND, and the top 25 account for 100.0%.
Across the largest Rare Disease Biotech peers, institutional ownership levels are: IRLA (23.9%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.